More on MDGL
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $542.61 |
|
|||
| Open | $536.82 | ||||
| 52 Wk High | $18.24 | ||||
| 52 Wk Low | $6.60 | ||||
| Day High | $547.92 | ||||
| Day Low | $535.60 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 177,171 | ||||
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals adds J&J executive to its board
- Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
- Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform
- Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays
- Madrigal Pharma (MDGL) Tops Q2 EPS by 76c
- H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
- Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays
Entities mentioned with MDGL
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Goldman Sachs | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Show More...
